In this video, Motley Fool health-care analyst David Williamson talks about some of the biggest investing stories in the health-care space today. He tells us about Pfizer (NYSE: PFE) and Bristol-Myers Squibb's (NYSE: BMY) latest European victory, a major insurance win for obesity-drug maker VIVUS (NASDAQ:VVUS), a huge vote of share-price confidence for Sarepta (NASDAQ: SRPT) and its drug for Duchenne muscular dystrophy, and a big tumble for St. Jude Medical (NYSE: STJ) after another problem with one of its products.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/20/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.